Sign In
Buy AXSM
$233.49
+11.33 (+5.10%)
At Close: Jun 03, 2026
Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results
08:15am, Tuesday, 31'st Dec 2024
On Monday, Axsome Therapeutics, Inc. AXSM released data from ACCORD-2, ADVANCE-2, and long-term safety trials AXS-05 (dextromethorphan-bupropion) in Alzheimer's disease agitation.
Axsome Therapeutics, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session
08:13am, Monday, 30'th Dec 2024
U.S. stock futures were lower this morning, with the Dow futures falling more than 50 points on Monday.
Axsome's drug for Alzheimer's disease agitation meets main goal in late-stage study
07:15am, Monday, 30'th Dec 2024
Axsome Therapeutics said on Monday its experimental treatment for the Alzheimer's disease-related agitation met the main goal of a late-stage trial.
ACCORD-2 Phase 3 trial in Alzheimer's disease agitation achieves primary endpoint compared to placebo (p=0.001, time to relapse)
Why Is Axsome (AXSM) Down 0.1% Since Last Earnings Report?
12:36pm, Thursday, 12'th Dec 2024
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?
Axsome: Focus On AXS-12 Targeting Narcolepsy, Which Just Released Positive Data
10:32am, Friday, 29'th Nov 2024
Axsome's AXS-12 met its primary endpoint in a Phase 3 study, significantly reducing cataplexy attacks in narcolepsy patients, positioning it for an NDA submission. The narcolepsy market is substantial
Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says
01:23pm, Wednesday, 27'th Nov 2024
On Tuesday, Axsome Therapeutics Inc AXSM said AXS-12 statistically significantly reduced the frequency of cataplexy attacks compared to placebo (p=0.017, primary endpoint) in Phase 3 ENCORE trial.
Axsome's Q3 Earnings Beat, Auvelity Drives Sales Growth, Stock Up
12:10pm, Wednesday, 13'th Nov 2024
AXSM posts better-than-expected third-quarter results. Stock rises in response to the results and strong sales uptake of Auvelity.
Axsome Therapeutics, Inc. (AXSM) Q3 2024 Earnings Call Transcript
02:02pm, Tuesday, 12'th Nov 2024
Axsome Therapeutics, Inc. (NASDAQ:AXSM ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Darren Opland - Director, Corporate Communications Herriot Tabuteau - CEO Ni
Axsome Therapeutics Q3 Earnings: Stay For The Near Term Catalysts, Then Sell
01:17pm, Tuesday, 12'th Nov 2024
Axsome Therapeutics' Q3 2024 earnings report shows a revenue beat with $104.8m, up 81% YoY, but net loss increased to $(64.6m). Despite positive market response and promising pipeline candidates, Axso
Axsome Therapeutics (AXSM) Reports Q3 Loss, Tops Revenue Estimates
09:16am, Tuesday, 12'th Nov 2024
Axsome Therapeutics (AXSM) came out with a quarterly loss of $1.34 per share versus the Zacks Consensus Estimate of a loss of $1.38. This compares to loss of $1.32 per share a year ago.
Will These 5 Biotech Stocks Surpass Q3 Earnings Forecasts?
11:50am, Monday, 11'th Nov 2024
Let's look at five biotech and drug companies, AZN, NVAX, AXSM, TBPH and PRTA, slated to release their third-quarter 2024 results this week.
Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024
07:00am, Friday, 08'th Nov 2024
NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system
Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for
11:05am, Tuesday, 05'th Nov 2024
Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024
07:00am, Tuesday, 29'th Oct 2024
NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system
